Agonist
Back to library
GLP-1Subcutaneous

Tirzepatide

Also known as: Mounjaro · Zepbound · Tirz · GIP/GLP-1

Dual GIP and GLP-1 receptor agonist. The GIP component appears to amplify GLP-1 satiety effects and improves insulin sensitivity beyond GLP-1 monotherapy.

At a glance

Half-life
4.8 days
Common route
Subcutaneous
Typical dose range
2,500–15,000mcg
Stability (reconstituted)
42days refrigerated

Best timing

Once weekly. Many users prefer Friday/Saturday dosing so peak GI side effects fall on the weekend.

Contraindications

  • Personal or family history of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • History of pancreatitis
  • Severe GI disease
  • Pregnancy

Watch symptoms

  • Nausea, vomiting, constipation alternating with diarrhea
  • Sulfur or rotten-egg burps
  • Injection site reactions
  • Resting heart rate increase
  • Signs of pancreatitis or gallbladder disease

Citations

The primary literature.

  1. 01Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)PubMed
  2. 02Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2)PubMed
Back to library